A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).

Administered By

Awarded By

Contributors

Start/End

  • February 21, 2022 - January 31, 2025